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Abstract 
 
Objective 
To test the practicality, acceptability and feasibility of recruitment, data collection, 
blood pressure monitoring and pharmaceutical care processes, in order to inform the 
design of a definitive randomised controlled trial of a pharmacist complex 
intervention to stroke patients in their own homes. 
 
Methods  
Patients with new stroke from acute, rehabilitation wards and a neurovascular clinic 
(NVC) were randomised to usual care or to an intervention group who received a 
home visit at 1, 3 and 6 months from a clinical pharmacist.  Pharmaceutical Care 
comprised medication review, medicines and lifestyle advice, pharmaceutical care 
issue (PCI) resolution and supply of individualised patient information. A 
pharmaceutical care plan was sent to the General Practitioner and Community 
Pharmacy. Blood pressure and lipids were measured for both groups at baseline and at 
6 months. Questionnaires covering satisfaction, quality of life and medicine adherence 
were administered at 6 months.  
Results 
Of 430 potentially eligible patients, 30 inpatients and 10 NVC outpatients were 
recruited. Only 33/364 (9.1%) NVC outpatients had new stroke.  Thirty five patients 
completed the study (intervention = 18, usual care = 17).  
Questionnaire completion rates were 91.4% and 84.4% respectively. Blood pressure 
and lipid measurement processes were unreliable. From 104 identified PCIs, 19/23 
(83%) recommendations made to General Practitioners were accepted. 
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Conclusions  
Modifications to recruitment is required to include patients with TIA. Questionnaire 
response rates met criteria but completion rates did not which merits further analysis. 
Lipid measurements are not necessary as an outcome measure. A reliable BP 
monitoring process is required. 
 
 
 
Key Messages: 
 
What is known 
x Recurrent stroke accounts for approximately 25% of all strokes 
x Systematic reviews of complex interventions in stroke conclude that few have 
been adequately developed or evaluated 
x There is scope for pharmaceutical care to optimise stroke secondary 
prevention 
 
This study adds: 
x Consider inclusion of patients with TIA to improve recruitment rate. Face to 
face invitation to participate is more successful than postal invitation 
x If BP is to be used as an outcome, a reliable process for measurement is 
required 
x Although questionnaire return rate was acceptable, reasons for lower 
completion rates require investigation 
x Iterative feasibility testing is necessary to inform an randomised control trial 
 
 
 
INTRODUCTION 
National and European stroke guidelines state that patients requiring admission to 
hospital should be admitted to a stroke unit staffed by a coordinated multidisciplinary 
stroke team.[1, 2] In the acute setting this usually includes a specialist clinical 
pharmacist whilst on discharge from hospital, pharmaceutical care is generally 
managed by non-specialist community pharmacists. A proportion of stroke patients on 
discharge do not have contact with the community pharmacist because they are unable 
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to visit the pharmacy in person.[3, 4] 4XDOLWDWLYHVWXGLHVLQVWURNHSDWLHQWV¶KRPHV
have identified the barriers and difficulties which patients experience taking their 
medicines.[3, 4] Stable medicine routines, appropriate medicine and illness beliefs, 
communication at the secondary/ primary care interface, individualised information 
and practical help from healthcare staff with medicine organisation are the key factors 
in optimising medicine taking behaviour.[3, 4] 
Medication and lifestyle modification may reduce recurrent vascular events in patients 
with stroke by 80% over five years.[5] One third of stroke patients discontinue 
secondary prevention medication within one year[6] and recurrent stroke accounts for 
approximately 25% of all strokes.[7] 
There is evidence that pharmacists can manage control of blood pressure (BP) in 
diabetics with cardiovascular disease to reach targets.[8] In stroke patients, a 
systematic review of interventions to improve BP through adherence to 
antihypertensive medicines included one pharmacist led study.[9] The intervention 
consisted of 6 x 1 hour face to face counselling sessions in 160 patients for 6 months 
in a hospital outpatient clinic.  The design and reporting of this study limits its 
interpretation.[10] Pharmacist telephone interventions in stroke patients have been 
shown to help reach secondary stroke prevention goals.[11] The Cochrane review of 
interventions in secondary prevention of stroke[12] concludes that there is no clear 
evidence of change in modifiable risk factors with educational or behavioural 
interventions alone without also organisational changes. Systematic reviews have 
FRQFOXGHGWKDWIHZFRPSOH[LQWHUYHQWLRQVLQVWURNHKDYHEHHQµDGHTXDWHO\Geveloped 
RUHYDOXDWHG¶GXHWRPXOWLSOHSULPDU\RXWFRPHVLQVXIILFLHQWVWDWLVWLFDOSRZHULQJDQG
poor intervention development.[12,13] Our complex intervention is based on previous 
pharmaceutical needs assessment.[3] We propose to undertake a randomised 
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controlled trial (RCT)  to evaluate a complex intervention [14] of structured 
pharmaceutical care (Appendix 1) delivered by a pharmacist to stroke patients in their 
own homes with the hypothesis that the intervention will increase the proportion of 
patients reaching target blood pressure (BP).  In line with Cochrane,[12] elements of 
education and behavioural intervention for patients and their carers/stroke service 
providers and organisational interventions including associated communication and 
follow up with the multidisciplinary team (MDT) would be included. This pilot study 
assesses the feasibility of the processes required for an RCT to define an appropriate 
primary outcome measure and potential sample size for a future RCT.  
 
 
OBJECTIVES 
This pilot study aimed to test the practicality, acceptability and feasibility of 
recruitment, data collection, BP monitoring and pharmaceutical care processes in 
order to inform the design of a definitive RCT of a pharmacist complex intervention 
to stroke patients in their own homes. 
Pilot Study Outcomes 
The outcome was determination of feasibility of the following processes: 
x Recruitment - consent rate, drop out rate, eligibility criteria, randomisation 
process 
x Data collection ± availability and accessibility of clinical and prescribing data 
from primary and secondary care patient records, questionnaire return and 
completion rates 
x BP measurement - setting/method/operator, drug treatment effect, variability 
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x Pharmaceutical care ± process of identification and method of resolving care 
issues 
 Pilot study criteria (proposed ± agreed by expert group consensus) 
Recruitment ± two thirds of inpatients eligibility, 50% consent and 10% attrition 
Data Collection ± Clinical and prescribing data accessible at time of retrieval from 
hospital and GP computer systems. 90% questionnaire return and completion rates. 
BP ± consistency (90%) in measurements taken by clinical pharmacy researcher and 
nurse in different settings. 
Pharmaceutical care ±identified care issues are recorded, categorised according to an 
internationally recognised method [15], acted upon and followed up. 
 
Ethics 
The local Research Ethics Committee approved the study in June 2009 (09/S1103/21) 
and local National Health Service Research and Development Management approval 
was granted. 
METHOD 
Participants and setting 
Approximately 1400 stroke patients per annum are diagnosed in the regional health 
organisation which has 3 acute stroke wards, 3 stroke rehabilitation centres and an 
outpatient neurovascular clinic (NVC). 
Inclusion criteria 
Patients with a confirmed diagnosis of stroke who were either discharged home from 
an inpatient hospital unit or attended the NVC. 
Exclusion criteria 
 7 
(1) Dysphasia (assessed by Speech and Language therapy) or confusion (assessed by 
the Mini Mental State Examination (MMSE) score < 24) severe enough to prevent 
patients from understanding the rationale for the study or giving informed consent 
(2) Discharge to long term nursing care 
(3) Terminal illness 
(4) Inability to nominate a community pharmacy 
Recruitment 
Patients due for discharge from acute and rehabilitation stroke units were identified by 
the ward team who obtained permission from potentially eligible inpatients to be 
approached by the clinical pharmacist researcher who visited the patient to discuss the 
study, provide a patient information sheet and obtain consent. Stroke patients 
attending the outpatient NVC were identified through the electronic patient 
management system and posted an invitation letter, patient information sheet and 
consent form for postal return.   
Patients were included from all care settings as previous work by the research team 
has shown that all stroke patients have pharmaceutical care needs.[3] 
Randomisation 
Randomisation would be required in a definitive study to compare outcomes between 
groups. Randomisation to intervention or usual care group was undertaken using 
sequentially numbered opaque envelopes prepared by an independent person to ensure 
allocation concealment. Previous work suggests patients living alone have more 
problems with their medicines.[3] Therefore stratification was applied prior to 
randomisation to ensure equal numbers of living alone in each group. The researcher 
and wider healthcare team were not blinded to the treatment arm of the study.  
Data Collection and Intervention 
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The intervention tool was designed from previous work[3,16,17] and includes a 
pharmaceutical care plan and individualised patient information sheet (Appendix 1).  
To populate the intervention tool, the clinical pharmacist researcher collected data 
from clinical records and from patient interview whilst in hospital (inpatients) or at 
the one month visit (NVC outpatients). The following data were collected: 
x Blood pressure and cholesterol measurements 
x Current medication  
x Lifestyle records (smoking, diet, alcohol, physical exercise) 
x Social and practical support ( e.g. difficulty in organising repeat prescriptions, 
physically taking medicines) 
x MMSE 
An assessment was made of current medication against stroke evidence based 
guidelines for secondary prevention taking into account co-morbidities and the need 
for additional therapy. Suitability of doses and medication type was assessed for the 
individual taking into account medicine interactions, renal and liver function, co-
morbidities and potential side effects. Medicines were also assessed for suitability of 
formulation and medicine device in relation to stroke patient physical abilities. 
Pharmaceutical care issues (i.e. problems or potential problems) were identified by the 
clinical pharmacist researcher, recorded on the tool and followed up with the most 
appropriate member of the multidisciplinary team. 
A copy of the individualised patient information sheet was provided to patients after 
the interview and the intervention tool was sent to thHSDWLHQW¶V*HQHUDO3UDFWLWLRQHU
(GP) and nominated Community Pharmacy. 
At 1, 3 and 6 months after discharge or outpatient NVC visit, the clinical pharmacist 
researcher visited each patient in their own home to identify additional issues which 
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may have arisen since last visit and resolve outstanding issues which had not been 
satisfactorily concluded. 
These time points were selected as it is known that non-adherence occurs more often 
with new than existing medicines,[18] a USA study has shown that 25% of 2888 
patients discontinued one or more stroke medicines 3 months post discharge[19] and 
adherence declines substantially after the first 6 months of treatment.[20] Prior to each 
KRPHYLVLWWKHFOLQLFDOSKDUPDFLVWUHVHDUFKHUYLVLWHGWKHSDWLHQW¶V*3SUDFWLFHto 
update the intervention tool with relevant data, for example medicine changes and 
blood pressure (BP) results. Following each home visit, a letter was sent to the GP and 
community pharmacist recording issues and recommended actions where appropriate 
with an invitation to discuss with the clinical pharmacist researcher if required. 
All patients were posted a questionnaire for self completion after the 6 month home 
visit for return in a stamped addressed envelope to another member of the research 
team blinded to treatment allocation. Quality of life using the Euroquol-5D, a 
questionnaire previously used in stroke patients, adherence (MARS ± Medication 
Adherence Rating Scale), medicine beliefs (BMQ - Beliefs about Medicines 
Questionnaire) and depression (HAD - Hospital Anxiety and Depression) were 
measures included in the questionnaire.[21-24] A patient satisfaction section used a 
modified version of a validated satisfaction questionnaire and included additional 
questions for the intervention group specifically regarding the 1 and 3 month home 
visits.[25-27] The MMSE was repeated at the 6 month home visit to confirm patient 
ability to complete the questionnaire was unchanged. If changed, the patient would be 
transferred to the usual care group. Pharmaceutical care issues were identified during 
the clinical medication review process and recorded throughout the study in the 
 10 
intervention group and at the 6 month home visit in both groups. Issues requiring 
resolution were included in a letter to the GP for both groups. 
BP and cholesterol measurements were accessed at the time of the 6 month home visit 
and the proportion of patients meeting targets compared. 
The clinical pharmacist researcher measured BP in the intervention group at each 
home visit and in the usual care group at the 6 month home visit. All patients were 
required to attend a short clinic appointment at the Wellcome Trust Clinical Research 
Facility (WTCRF) at six months for assessment of outcomes (BP, self reported 
adherence and patient knowledge questionnaire) by independent nurses blinded to 
randomisation to minimise potential bias. Patients unable to attend the WTCRF clinic 
were visited by nurses in their own home. 
Usual care 
Patients were discharged from all settings following standard procedures. This group 
received one home visit at 6 months to collect comparison data to the intervention 
group. Ability to provide a clinical pharmacy service to inpatients may have affected 
the level of pharmaceutical advice the usual care group received prior to discharge.  
 
RESULTS 
Recruitment Process 
Of 66 inpatients and 364 NVC outpatients identified as being potentially eligible for 
inclusion, 331 outpatients were excluded on the basis of having a Transient Ischaemic 
Attack (TIA) or diagnosis other than stroke and four inpatients did not agree to be 
approached by the researcher. Of the 95 invited to participate, 10 inpatients were 
excluded, 45 declined, resulting in 30 inpatients and 10 NVC outpatients being 
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randomised. Eighteen patients in the intervention group and 17 in the usual care group 
completed the study as 5 were lost to follow up (Figure 1).  
Recruitment occurred between July and November and participants were followed up 
over the following six months. The two groups were similar demographically (Table 
1). 
Table 1 Baseline characteristics*    
 
Characteristic 
Intervention 
group 
(n=18) 
Control 
group 
(n=17) 
P value 
Mean Age (SD) 74.2 (8.8) 71.9 (7.3) 0.401 
Sex, female (%) 9 (50.0) 5 (29.4) 0.305 
Living alone (%) 4 (22.2) 5 (29.4) 0.711 
 
Type of stroke (%) 
    lacunar anterior 
    partial anterior 
    partial occipital 
    total anterior 
    intracerebral    
    haemorrhage  
 
 
5 (27.8) 
9 (50.0) 
0 
3 (16.7) 
1 (5.6) 
 
 
6 (35.3) 
7 (41.2) 
3 (17.6) 
1 (5.9) 
0 
 
 
 
0.725 
0.854 
0.104 
0.603 
1.000 
History of stroke care 
setting at recruitment(%) 
   
    acute stroke unit only 6 (33.3) 7 (41.1) 0.897 
    acute stroke and   
    rehabilitation unit 
7 (38.9) 6 (35.3) 0.826 
    neurovascular  
    outpatient clinic 
 
5 (27.8) 4 (23.5) 0.706 
Mean Systolic BP 
mmHg (SD) 
140.7 (21.8) 128.5 
(19.6) 
0.087 
Mean Diastolic BP 
mmHg (SD) 
78.4 (12.7) 72.5 (8.4) 0.057 
BP < 140/85 mmHg 
(diabetes 130/80 mmHg)  
6 (33.3) 9 (52.9) 0.407 
Mean Total cholesterol 
mmol/L (SD) 
4.4 (1.2) 4.4 (1.1)  
Baseline cholesterol < 5 
mmol/L (%) 
11 (61.1) 13 (76.5) 0.471 
Community pharmacy 
medicines provision 
    patient collects 
    carer collects 
    pharmacy delivers 
 
 
7 (38.9) 
4 (22.2) 
7 (38.9) 
 
 
9 (52.9) 
2 (11.8) 
6 (35.3) 
 
 
0.621 
0.658 
0.826 
* numbers of patients unless otherwise stated 
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Data collection process 
The hospital and GP practice patient record systems were accessible for all 
participants.  
At recruitment, total cholesterol and low density lipoprotein (LDL) measurements 
were unavailable in 5 and 27 patients respectively, resulting in clinical and prescribing 
data being available for only 8 (23%) patients.  
During the six month study period, complete sets of clinical and prescribing data were 
available for 16 of 35 (46%) patients. For 1 patient in the usual care group, not a 
single BP measurement was recorded.  Monitoring of cholesterol and LDL was not 
undertaken for 7 and 19 patients respectively. 
90% of questionnaires were returned. Completion rates for the questionnaires are 
shown in Table 2. 
Table 2 Questionnaire completion rates, n(%) 
 
Questionnaire Intervention (n=18) Usual care (n=17) 
BMQ 16 (88.9) 15 (88.2) 
Perception of benefit 16 (88.9) 15 (88.2) 
MARS 16 (88.9) 11 (64.7) 
Euroqol 5D 16 (88.9) 14 (82.4) 
Euroqol thermometer 17 (94.4) 14 (82.4) 
HAD 17 (94.4) 11 (64.7) 
Satisfaction 14 (77.8) 13 (76.5) 
 
Blood Pressure Process 
In the intervention group, intra individual patient BP measurements varied irregularly 
at 1 ,3 and 6 months. There was also variation between the researcher measurements 
in the home setting and the nurse measurements in the home setting or the clinic. At 
the 6 month follow up, the mean (SD) number of BP measurements per patient taken 
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in primary care was 2.2 (1.0) for the intervention group and 1.9 (1.7) for the usual 
care group.  One patient had no BP measurements recorded. Five participants opted to 
have the WTCRF visit in their own home.  
Pharmaceutical Care 
The total number of care issues identified in the intervention group was 104 (mean 5.8 
(2.1) per patient range 3- 10) which fell into the following categories[17] : additional 
medicine (n=10), unnecessary medicine (n=1), wrong medicine (n=1), dose too low 
(n=5), adverse drug reaction (n=11), interaction (n=8), inappropriate compliance 
(n=18) and monitoring and patient advice (n=50). Monitoring included 
recommendations for checking records for laboratory tests, International Normal 
Ratio (INR) and BP measurements. Written and verbal information was provided 
about medicines and lifestyle behaviours. Pharmaceutical Care Issues identified from 
observation of medicine taking behaviour in patients own homes included a patient 
taking two brands of the same antihypertensive, doses remaining in medication 
compliance aids, stockpiling medicine, use of expired medicines and dispensing 
errors. 
In the intervention group, 23 recommendations were made to GPs, of which 19 (83%) 
were accepted (Table 3). 
Table 3 Pharmaceutical care recommendations to GP (n=23) 
 
Additional drug required 
Calcium/Vitamin D recommended in two patients with osteoporosis  
Proton pump inhibitor recommended for aspirin associated dyspepsia  
Additional antihypertensive recommended for five patientsa 
Unncessary drug 
Recommended to stop dipyridamole as warfarin started  
Wrong drug 
Recommended changing dipyridamole to licensed modified release formulation 
Dosage too low 
Recommended increasing dose of levothyroxine based on thyroid function tests  
Recommended titrating dose of antihypertensive in two patients 
Adverse drug reaction  
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Recommended discontinuing dipyridamole in patient experiencing headache 
Recommended increasing to indicated dose of proton pump inhibitor for GI prophylaxis  
Recommended stopping tamsulosin in patient with postural hypotension  
Recommended monitoring potassium in patient with hyperkalaemia recently started 
spironolactone** 
Recommended check of creatine kinase in suspected statin induced myopathy  
Interaction 
Recommended change of statin in patient prescribed simvastatin and carbamazepine  
Inappropriate compliance  
Recommended warfarin added to multicompartment compliance aid following risk 
assessment  
Other 
Recommended malnourished patient referred to dieticianb  
Recommended patient with high HbA1c referred to diabetes clinic  
Recommended follow up of blood pressure following isolated high result 
a recommendation not accepted in two patients 
b recommendation not accepted 
 
DISCUSSION 
Strengths and weaknesses 
No data were available from non respondents which could limit generalisability. 
One single researcher may not reflect practice which could influence the 
generalisability but a strength was that the researcher was a clinical pharmacist and 
the intention is that the intervention would be delivered by a qualified prescribing 
pharmacist. 
Recruitment 
The proportion of patients attending the NVC with a diagnosis of new stroke was 
small (9.1%)  and only a third of those eligible consented to participate compared to 
two thirds in the inpatient group. There is potential to increase eligibility by including 
those with confirmed diagnosis of TIA in addition to stroke as issues are similar. 
Higher recruitment of inpatients may have been influenced by personal contact with 
the researcher allowing the opportunity for questions and clarification. A similar 
method should be used for NVC outpatient recruitment in a definitive RCT as 
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opposed to the postal method used in this study. This may also elucidate why patients 
refused to participate as most (22/45) failed to give a reason or reply.  
Consideration should be given to screening patients at the first visit to identify those 
with greater pharmaceutical care needs to determine whether a second face to face 
visit is necessary. Recruitment may be unaffected but the intervention may be more 
efficient. 
Consideration should be given to further stratifying patients according to complexity 
of pharmaceutical care needs. This would require to be taken into account when 
calculating the sample size for a future study. 
Data Collection 
Data collection from hospital and GP practices was straightforward but electronic 
transfer methods should be explored to reduce the need for GP practice visits. 
Lack of GP measurement of total and LDL cholesterol was the main reason for the 
low percentage of available data. The rate was too low for meaningful analysis.  
Given this and the evidence that stroke secondary prevention should include 
cholesterol lowering agents irrespective of blood total cholesterol,[1] cholesterol 
measurement would be excluded from a definitive RCT as it would not be a 
meaningful outcome measure.  
Questionnaires were distributed by post and given the attrition rate was only 10%, this 
method is acceptable. Overall completion rate did not meet the set criterion and was 
less in the usual care group, possibly due to less researcher contact and was lowest for 
the MARS and HAD sections. It would be desirable to review the content and explore 
a shorter version of the questionnaire. 
Blood Pressure 
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The frequency of routinely collected BP measurements from GP records was 
insufficient for use as an outcome measure in a future study. The intra individual 
variation observed in single BP measurements taken by the clinical pharmacist 
researcher and research nurses suggests that a more reliable method of BP 
measurement is required if BP is to be used as a future measure of effect of an 
intervention. Although Ambulatory blood pressure monitoring (ABPM) is 
recommended by the National Institute for Health and Care Excellence for the 
accurate diagnosis of hypertension, it may be burdensome for patients. Other studies 
[12,29] have taken multiple readings, have brought patients to clinics or used home 
BP monitors, which are also burdensome. There is a need to further test for patient 
acceptability to estimate size of effect for future power calculations. A future study 
could not rely on routinely recorded BP measurements by primary care clinicians. BP 
measurements require to be taken by investigators as part of a definitive RCT. 
Pharmaceutical care 
Communication of care issues with GPs was by letter and although there was high 
acceptance of recommendations, it would be desirable to align with local emerging e-
communication and paperlite methods. 
The nature of the identified pharmaceutical care issues (Table 3) supports the benefit 
from a pharmacist delivered intervention. Although home visits allowed identification 
of issues that otherwise would not be identified, telephone contact should be 
considered as an option for follow up consultations. An RCT published  in abstract 
form only, showed that pharmacists providing telephone follow up to 30 stroke 
patients versus usual care improved adherence to secondary prevention medicines 
(anti-thrombotics specifically) and achieved BP, lipid level and glucose control goals, 
an effect sustained up to one year.[11]  
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A prescribing pharmacist delivering the intervention in the main study has the 
potential to reduce the reliance on the GP to make changes and is in line with the 
current Scottish Government vision as set out in the Prescription for Excellence 
document.[28] This is supported by a recent RCT which found a prescribing 
pharmacist increased the proportion of patients with TIA or minor stroke reaching 
target BP and LDL levels compared to nurses reporting results to primary care 
physicians.[29] 
A pharmacist led intervention targeting stroke patients¶ medicine needs in their own 
homes would concur with the LoTS care trial recommendations of providing a 
specialised bespoke service.[30]  
Usual care  
There were no differences in feasibility of data collection or questionnaire completion 
rates in the usual care group as compared to the intervention group. The 
contamination risk from interventions made by community pharmacists and other 
MDT members is unknown but the risk is similar for both intervention and usual care 
groups. 
CONCLUSION 
This study highlighted that before designing a definitive RCT, the following need to 
be considered: modification of the recruitment and invitation process and inclusion of 
patients with TIA to increase eligibility and participation; removal of cholesterol 
measurements as a meaningful outcome measure; a reliable BP monitoring process 
and further qualitative analysis to improve questionnaire completion rates.  
This pilot study tested the feasibility of a number of processes. Findings suggest there 
is a need for further feasibility testing of the process of BP monitoring and its 
acceptability to patients as this is the proposed outcome for the definitive RCT. 
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